EPCORITAMAB-BYSP

1338 reported adverse events

Drug classes: Bispecific CD20-directed CD3 T Cell Engager [EPC]

EPCORITAMAB-BYSP is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 HIGH GRADE B-CELL LYMPHOMA REFRACTORY 4 1.0000
1 DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY 235 0.2482
2 HAEMORRHAGIC GASTROENTERITIS 1 0.2000
3 B-CELL LYMPHOMA REFRACTORY 12 0.1348
4 EUSTACHIAN TUBE STENOSIS 1 0.1250
5 FOLLICULAR LYMPHOMA REFRACTORY 7 0.1077
6 ACUTE NECROTISING MYELITIS 1 0.1000
7 ATYPICAL LYMPHOCYTES INCREASED 2 0.0909
8 HIGH GRADE B-CELL LYMPHOMA RECURRENT 1 0.0909
9 KNUCKLE PADS 2 0.0870
See all enriched reactions for EPCORITAMAB-BYSP